GST refund drove Dhanuka’s highest-ever EBITDA margin

Dhanuka Agritech Limited — Q4 & FY26 Earnings Call (Quarter & Year ended 31 Mar 2026) | Call held 19 May 2026

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes “resilient operational and financial performance” and “constructive” medium-to-long-term outlook.
• Confident framing on shareholder actions and growth: 100% dividend, buyback at a premium, and ESOP approval, plus guidance for FY27 “low double digits”.
• However, they also acknowledge meaningful near-term headwinds (weather volatility, weak channel liquidity, GST refund reversal), but the net narrative remains positive.

2. Key Themes from Management Commentary

• Resilient FY26 performance despite industry headwinds
• Q4 revenue growth ~9% YoY; PAT up; EBITDA up.
• Weather/climate volatility as a structural demand driver
• Unseasonal rainfall and monsoon uncertainty affecting sowing behavior, crop economics, and farmer sentiment.
• Margin support largely from one-off factors
• Q4 EBITDA “highest ever” attributed to GST refund timing.
• Strategic expansion via Bayer product acquisitions + backward integration
• Triadimenol & Iprovalicarb transition: Bayer continues commercialization in many countries while Dhanuka appoints distributors and prepares India manufacturing/formulation.
• Dahej plant ramp-up remains central but with near-term variability
• Dahej sales and EBITDA discussed; Dahej remains loss-making on EBITDA (though improving vs prior year).
• Biostimulants/biologicals regulatory overhang
• FY26 biostimulant impact referenced as a headwind; FY27 expects normalization via approvals/launches.
• Cost discipline and working capital management
• Opex reduction in Q4; receivables/inventory management discussed as a differentiator (with caveats about inventory spikes due to strategic buying and slower movement).

3. Q&A Analysis

Theme A: Bayer-acquired products—launch status, registrations, and go-to-market

• Core questions
• Whether new products/customers were added in the acquired Bayer portfolios (Triadimenol, Iprovalicarb).
• How registration and distributor appointment challenges evolved.
• Timeline for manufacturing shift and overseas revenue recognition.
• Management response
• Bayer continues commercialization in most markets; Dhanuka appointed customers/distributors in ~5 countries, advanced discussions in ~10 more.
• Registration not the “bigger issue”; distributor appointment + supply chain are the main challenges.
• India actions: Melody Duo already in portfolio; Triadimenol formulation shifting to India in FY26; Iprovalicarb technical production starting by end of FY26; formulation shifting for both products to India for supply chain efficiency.
• Notable/partial or evasive elements
• Overseas revenue timing is described qualitatively (“portion in FY27, full from next year”), but exact country-by-country revenue ramp is not fully quantified.

Theme B: Q4 margin outperformance—what drove EBITDA/gross margin

• Core questions
• Whether there was market “pre-placement”/channel stuffing.
• Drivers of highest-ever EBITDA margin despite weaker new product contribution.
• GST refund quantum and its impact.
• Management response
• No significant pre-placement; placement similar to prior year.
• EBITDA margin expansion largely due to GST refund timing:
  • Full-year GST refund Rs. 29 cr, with Q4 Rs. 14.5 cr.
• Dahej details provided:
  • Dahej sales Q4 Rs. 8 cr vs Rs. 15 cr (YoY).
  • Dahej EBITDA loss: ~Rs. 13 cr loss (FY basis); Q4 not explicitly stated as breakeven.
• Unusually strong/clear answer
• Attribution of EBITDA peak to GST refund is direct and specific (unlike many calls where drivers are blended).

Theme C: FY27 guidance—what offsets headwinds

• Core questions
• How “low double digit” growth is achievable if base business may degrow.
• Impact of GST refund absence, net economic benefit changes, and Bayer consolidation timing.
• Breakdown of price vs volume growth assumptions.
• Management response
• Headwinds quantified:
  • ~Rs. 40 cr impact from GST refund absence + net economic benefit hit.
• Offsets:
  • Buy stimulant re-introduction (qualitative timing/impact).
  • Bayer sales consolidation is phased: portion in FY27, full ramp from later year.
• Price/volume:
  • Volume growth could differ by year-end by ~2%, with price growth > volume growth.
• Margin:
  • EBITDA margin decline of ~100 bps assumed due to gross margin decline from GST refund reversal and net economic benefit reduction; management expects no gross margin expansion and aims to maintain 25–26 gross margins (net-net).
• Partial/evasive elements
• The “buy stimulant” offset is mentioned but not tightly quantified against the Rs. 40 cr headwind.
• Bayer contribution numbers are provided in fragments; full reconciliation to guidance is not fully laid out.

Theme D: Input costs, availability, and pass-through

• Core questions
• Import material availability for Kharif; whether protected from shortages.
• Basket input price inflation and pass-through to customers.
• Management response
• Availability: not a challenge; imports mainly from Japan/China.
• Price increases:
  • Imported material impact ~5–6% due to rupee depreciation.
  • Indigenously, some generics up 25–30% / 15%, but basket ~3–5%.
• Pass-through:
  • “Currently difficult” but expected to be passed on by Q2, with lag.
• Strong answer
• They provide a basket-level inflation range and timing of pass-through.

Theme E: Dahej plant—revenue targets, EBITDA, and guidance changes

• Core questions
• Why Dahej revenue forecast was downgraded (from earlier ~Rs. 100 cr target to lower).
• Whether Dahej is breakeven and what drives lower revenue.
• Management response
• FY26 forecast downgrade:
  • Earlier forecast Rs. 65 cr for FY26; delivered Rs. 50 cr.
  • FY27 forecast now Rs. 75 cr, down from earlier estimate of Rs. 100 cr.
• Rationale:
  • Registration/market ramp and international registration taking time.
  • Some products’ international registration and ramp delays; volumes from new international markets expected not very high initially.
• Credibility note
• They explicitly admit a downgrade vs earlier estimate (good transparency), but the underlying “why” is only partially explained.

Theme F: Biostimulants/biologicals—regulatory status and growth expectations

• Core questions
• Total revenue contribution of biologicals/biostimulants in FY25 vs FY26.
• How many products registered and expected growth in FY27.
• Management response
• FY25–26 biostimulant/biological revenue ~Rs. 70 cr; FY25 ~Rs. 110 cr.
• Launch/registration:
  • One molecule launched in FY25–26; three launches in June.
  • FY27 expectation: >Rs. 130 cr revenue for the category.
• Strong/clear
• Provides both historical category revenue and forward expectation.

Theme G: Channel inventory / working capital / GST refund accounting

• Core questions
• Whether channel inventory is elevated and could hurt later Kharif.
• Whether GST refund is included in Q4 revenues.
• Management response
• Inventory:
  • Rabi consumption better than Kharif; they don’t expect “lot of inventory lying out there.”
• GST refund:
  • Confirmed: “Yes. GST refund is a part of the revenues recognized during this quarter.”
• Potentially optimistic
• Inventory reassurance is qualitative; no hard channel-inventory metric is provided.

4. Guidance / Outlook

Explicit guidance (quantitative)

• FY27 revenue growth: “low double digits” (stated as guidance).
• FY27 margin / EBITDA direction:
• Assumes ~100 bps EBITDA margin decline (explained as gross margin decline due to GST refund absence + net economic benefit reduction).
• Management expects gross margin to be maintained at 25–26% (net-net).
• Biostimulants/biologicals FY27 revenue: > Rs. 130 cr.
• Dahej FY27 revenue: Rs. 75 cr (downgraded vs earlier ~Rs. 100 cr).
• 9(3) product revenue mix: maintain 25–26% (management says currently ~26% and expects to stay in that band).
• Price/volume growth (qualitative with numbers):
• Volume/value growth difference by year-end around ~2%, with price growth > volume growth.

Implicit signals (qualitative)

• Demand visibility remains weather/monsoon dependent (“linked to monsoon progression and reservoirs’ conditions”).
• Material near-term margin volatility due to GST refund timing and net economic benefit normalization.
• Overseas ramp is distributor- and registration-dependent, with phased revenue recognition (not immediate full consolidation).

5. Standout Statements (direct / revealing)

• GST-driven margin peak (very specific):
• “EBITDA is highest… largely because of the GST refund… Q4… Rs. 14.5 crores.”
• Distributor appointment is the real bottleneck for Bayer transition:
• “registration is not the bigger issue… major concern is appointing the distributors and managing the supply chain.”
• Guidance offset math acknowledged:
• “around Rs. 40 crore impact… compensated by the introduction of the buy stimulant again.”
• Dahej forecast downgrade admitted:
• “we have downgraded that forecast… forecasting Rs. 75 crores… lower than earlier estimate of Rs. 100 crores.”
• Biostimulants regulatory normalization path:
• “three will launch in the month of June” and expect >Rs. 130 cr in FY27.
• Channel inventory stance:
• “I don’t expect lot of that inventory lying out there in the market.”

6. Red Flags / Positive Signals

Red flags
– Dependence on one-offs for margin optics: EBITDA “highest ever” tied to GST refund timing; may not be repeatable.
– Guidance relies on offsets that are not fully quantified (e.g., “buy stimulant again” vs Rs. 40 cr headwind).
– Dahej revenue guidance cut vs earlier expectations suggests execution/ramp risk.
– Overseas ramp uncertainty: distributor appointment and registration transfer timelines remain fluid.

Positive signals
– Clear, specific explanations for margin drivers (GST refund quantum).
– Operational progress on strategic initiatives:
– Distributor onboarding in multiple countries; India manufacturing/formulation steps underway.
– Biostimulant launches scheduled (June) with explicit FY27 revenue target.
– Cost discipline demonstrated (Q4 other expenses down sharply; management attributes to expense control and principal support changes).

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• More Optimistic in FY26 Q4 call vs earlier quarters
• Q1 FY26: management guided for double-digit growth and expected EBITDA margin decline ~100 bps.
• Q2 FY26: still cautious due to herbicide weakness and biostimulant regulatory impact; also revised Bayer revenue expectations (exports delayed).
• Q3 FY26 (Feb 2026): explicitly said “bad phase is over now” and confidence in long-term double-digit CAGR.
• Q4 FY26 (May 2026): tone shifts further to resilient performance + shareholder value actions + FY27 low double-digit guidance.
• What changed
• More confidence in forward year numbers and less emphasis on “waiting for approvals” compared with earlier calls.
• Still acknowledges GST refund reversal and net economic benefit headwinds, but frames them as manageable.

b. Tracking Past Commitments vs Outcomes

• Bayer-related revenue timing
• Past statement (Q2 FY26, Oct 2025): exports/registration transfer delayed; “large part will be realized in the next year.”
• Current call: acknowledges phased consolidation; “portion in FY27… full sale from next financial year.”
• Assessment: ✅ Consistent (no contradiction; still phased).
• Dahej ramp / EBITDA positivity
• Past statement (Q3 FY26, Feb 2026): “working for making Dahej operations EBITDA positive in FY’27.”
• Current call: Dahej EBITDA still loss-making on FY basis (~Rs. 13 cr loss), and Q4 sales lower YoY.
• Assessment: ⏳ Delayed / not yet achieved (FY27 EBITDA positive remains a target, but FY26 outcome suggests ramp is still in progress).
• Biostimulant normalization
• Past statement (Q3 FY26, Feb 2026): hopeful approvals by end of quarter; launch by Q1 next year; “3 out of 4 molecules.”
• Current call: “one launched… three will launch in June” and FY27 category revenue >Rs. 130 cr.
• Assessment: ✅ Progressed, though timing appears to have shifted to June rather than earlier Q1 framing.

c. Narrative Shifts

• From “weather-driven weakness” to “mechanism-driven margin explanation”
• Earlier calls heavily emphasized rainfall/seasonality and channel inventory.
• In Q4 FY26, management more directly attributes margin outcomes to GST refund and net economic benefit mechanics.
• Biostimulants narrative becomes more execution-oriented
• Earlier: regulatory uncertainty and approvals queue.
• Now: specific launch timing (“three in June”) and revenue target.

d. Consistency & Credibility Signals

• Medium credibility
• Strength: management provides specific numbers (GST refund quantum, Dahej sales/EBITDA loss, biostimulant revenue and launch timing).
• Weakness: guidance downgrades (Dahej) and reliance on offsets without full quantification (buy stimulant vs Rs. 40 cr impact).
• No major contradictions, but some targets appear slower than earlier implied (Dahej EBITDA positivity).

e. Evolution of Key Themes

• Demand / weather: Stable as a recurring theme; still treated as the dominant near-term variable.
• Margins: Inflection from “gross margin cycle” discussion (earlier) to GST refund timing as a key driver of quarterly EBITDA optics.
• International expansion: Consistently framed as phased and execution-dependent (distributors + registrations).
• Regulatory (biostimulants): Moves from “queue/uncertainty” to “launch schedule + revenue target.”

f. Additional Cross-Period Insights

• Margin quality risk: Management’s “highest EBITDA margin” quarter is explicitly tied to GST refund; investors should treat this as non-recurring and not a pure operational improvement.
• Dahej ramp risk is real: Multiple quarters show Dahej as a growth lever, but FY26 outcomes (sales lower YoY in Q4; EBITDA loss persists) suggest ramp is not linear.
• Channel inventory reassurance is a recurring qualitative claim; unlike GST refund and other quantified items, channel-inventory risk is not backed by hard metrics in this call.